Table 1 Clinical characteristics of neuroblastoma patients
From: Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
| Â | Number | Percent of total |
|---|---|---|
MYCN status | Â | Â |
 Normal | 401 | 80.5 % |
 Amplified | 92 | 18.5 % |
 N.A. | 5 | 1.0 % |
INSS stage | Â | Â |
 1 | 121 | 24.3 % |
 2 | 78 | 15.7 % |
 3 | 63 | 12.7 % |
 4 | 183 | 36.7 % |
 4S | 53 | 10.6 % |
Age at diagnosis | Â | Â |
 <18 months | 300 | 60.2 % |
 >18 months | 198 | 39.8 % |
Sex | Â | Â |
 Male | 278 | 55.8 % |
 Female | 205 | 41.2 % |
 N.A. | 15 | 3.0 % |
High-risk patients | 176 | 35.3 % |